One of these drugs is tocilizumab, an immunoglobulin G1(IgG1) subclass antibody that inhibits the IL-6 receptor and that was tested in COVID-19 patients with elevated IL-6 levels, has exhibited several beneficial effects [74]. This evidence concerns the gene IL6 and COVID-19.